Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Pacira Biosciences Inc before investing.

In this article, we go over a few key elements for understanding Pacira Biosciences Inc’s stock price such as:

• Pacira Biosciences Inc’s current stock price and volume
• Why Pacira Biosciences Inc’s stock price changed recently
• Upgrades and downgrades for PCRX from analysts
• PCRX’s stock price momentum as measured by its relative strength

About Pacira Biosciences Inc (PCRX)

Before we jump into Pacira Biosciences Inc’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Pacira BioSciences, Inc. is a holding company for Pacira Pharmaceuticals, Inc. The Company's non-opioid treatments include EXPAREL (bupivacaine liposome injectable suspension), which is a long-acting, local analgesic for postsurgical pain management; ZILRETTA (triamcinolone acetonide extended-release injectable suspension), which is an extended-release, intra-articular (IA), corticosteroid injection indicated for OA knee pain, and Iovera, which is a novel handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. EXPAREL is used across multiple orthopedic procedures, including joint reconstruction, shoulder, spine, extremity procedures, and hip fractures. It is developing interventions to address debilitating conditions involving the sympathetic nervous system, such as cardiac electrical storm, chronic pain. Its clinical development programs include PCRX-201, and pMVL-Based Clinical Program.

Want to learn more about Pacira Biosciences Inc’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Pacira Biosciences Inc.

Pacira Biosciences Inc’s Stock Price as of Market Close

As of September 09, 2024, 4:00 PM, CST, Pacira Biosciences Inc’s stock price was $13.23.

Pacira Biosciences Inc is down 4.48% from its previous closing price of $13.85.

During the last market session, Pacira Biosciences Inc’s stock traded between $13.77 and $14.90. Currently, there are 46.17 million shares of Pacira Biosciences Inc stock available for purchase.

Pacira Biosciences Inc’s price-earnings (P/E) ratio is currently at 11.8, which is low compared to the Pharmaceuticals industry median of 27.9. The price-earnings ratio gauges market expectation of future performance by relating a stock’s current share price to its earnings per share.

Pacira Biosciences Inc Stock Price History

Pacira Biosciences Inc’s (PCRX) price is currently down 14.97% so far this month.

During the month of September, Pacira Biosciences Inc’s stock price has reached a high of $15.73 and a low of $13.11.

Over the last year, Pacira Biosciences Inc has hit prices as high as $35.95 and as low as $11.16. Year to date, Pacira Biosciences Inc’s stock is down 65.73%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Pacira Biosciences Inc Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of September 06, 2024, there were 2 analysts who downgraded Pacira Biosciences Inc’s stock and 7 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Pacira Biosciences Inc’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Pacira Biosciences Inc’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Pacira Biosciences Inc’s current valuation based on AAII’s Value Grade is a A, which means it is considered to be Deep Value.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Pacira Biosciences Inc (PCRX) by visiting AAII Stock Evaluator.

Relative Price Strength of Pacira Biosciences Inc

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of September 06, 2024, Pacira Biosciences Inc has a weighted four-quarter relative price strength of -27.40%, which translates to a Momentum Score of 12 and is considered to be Very Weak.

Want to learn more about how Pacira Biosciences Inc is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Pacira Biosciences Inc Stock Price: Bottom Line

As of September 9, 2024, Pacira Biosciences Inc’s stock price is $13.23, which is down 4.48% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Pacira Biosciences Inc stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.